Mitomycin C

Catalog No.S8146 Batch:S814602

Print

Technical Data

Formula

C15H18N4O5
Molecular Weight 334.37 CAS No. 50-07-7
Solubility (25°C)* In vitro DMSO 66 mg/mL (197.38 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Mitomycin C (Ametycine) is an antineoplastic antibiotic by inhibiting DNA synthesis, used to treat different cancers. Mitomycin C induces apoptosis in a caspases-dependent and Fas/CD95-independent manner.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.
Targets
DNA synthesis [1]
In vitro

Mitomycin C, by inducing DNA interstrand crosslinks, physically blocks DNA replication, recombination, and RNA transcription. This compound potentiates TRAIL-induced apoptosis in HCT116 (p53-/-) colon cancer cells and sensitizes TRAIL-resistant colon cancer cells HT-29 to the cytokine by through JNK-independent upregulation of death receptors. In different human cancer cell lines, such OVCAR-5 (ovary), HT-29 (colon), SK-N-MC (neuroblastoma), HEP-2 (liver), COLO-205 (colon), NIH-OVCAR-3 (ovary) and A-549 (lung) cells, this chemical shows cytotoxic activity.

In vivo

As the clinical first choice in superficial bladder tumors, in a rat bladder tumor model, Mitomycin C (400 μM) significantly prevents intravesical tumor growth.

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    HCT116 cells

  • Concentrations

    5 µM

  • Incubation Time

    24 h

  • Method

    Cells were pre-treated with 5 µM MMC for 24 h and then co-treated with TRAIL (25 ng/mL).
Animal Study:

[4]
  • Animal Models

    Rat bladder tumor model

  • Dosages

    400 μM

  • Administration

    Intravesical treatment

References

  • https://pubmed.ncbi.nlm.nih.gov/19748363/
  • https://pubmed.ncbi.nlm.nih.gov/22895172/
  • https://pubmed.ncbi.nlm.nih.gov/24791416/
  • https://pubmed.ncbi.nlm.nih.gov/24220494/

Customer Product Validation

MTT results of three HCC cell lines at 72 h after indicated treatments. Three independent experiments were carried out.

Data from [ , , Cancer Sci, 2018, 109(11):3450-3460 ]

Selleck's Mitomycin C Has Been Cited by 147 Publications

Client recruitment mechanism of the cytosolic Fe-S cluster assembly targeting complex [ EMBO J, 2026, 45(4):1264-1291] PubMed: 41484370
PTP4A3 contributes to pathological retinal neovascularization and vascular leakage partly through the PI3K-AKT signalling pathway [ Sci Rep, 2026, 16(1)14087] PubMed: 41851380
TRIM29 suppresses malignant progression in lung squamous cell carcinoma by shaping an immunosuppressive tumor microenvironment [ Sci Rep, 2026, 16(1):16952.] PubMed: 41963599
A Mechanotransduction-Aware Strategy for Enhancing MSC Potency via 3D Culture and Localized Delivery [ Cyborg Bionic Syst, 2026, 7:0552] PubMed: 41883986
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis [ Cell, 2025, S0092-8674(25)00625-7] PubMed: 40562027
Nano-polymeric platinum activates PAR2 gene editing to suppress tumor metastasis [ Biomaterials, 2025, 317:123090] PubMed: 39799696
Structural basis of Fanconi anemia pathway activation by FANCM [ EMBO J, 2025, 44(14):4013-4036] PubMed: 40447800
Efficient derivation of stable sheep embryonic stem cells opens a new avenue for agricultural and biomedical application [ J Adv Res, 2025, S2090-1232(25)00565-X] PubMed: 40712808
ARRB2 promotes cervical cancer progression via stabilizing CDC25A mRNA through m6A-IGF2BP1-dependent manner [ NPJ Precis Oncol, 2025, 9(1):80] PubMed: 40119070
Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer [ Cell Death Discov, 2025, 11(1):423] PubMed: 40998801

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.